Blinatumomab (Blincyto) — Clinical FAQs

Question 1

What is Blinatumomab FDA-approved to treat?

Accepted Answer

Blinatumomab is FDA-approved for the following oncology indications: 1. Relapsed or refractory Philadelphia chromosome-negative B-cell precursor ALL in adults and children (2014; TOWER trial) 2. Relapsed or refractory Philadelphia chromosome-positive B-cell precursor ALL in adults and children (2017) 3. B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1% (2018; MRD-positive B-ALL studies).

Question 2

How does Blinatumomab work (mechanism of action)?

Accepted Answer

Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that simultaneously binds CD19 on B-lineage tumor cells and CD3ε on T cells, forming an immunological synapse that activates polyclonal T cells independent of MHC presentation. This redirected lysis triggers perforin/granzyme-mediated cytotoxicity and Fas/FasL-mediated apoptosis of CD19+ malignant B cells. Serial T-cell killing allows a single T cell to eliminate multiple target cells. The molecule lacks an Fc region, minimizing Fc-receptor-mediated off-target effects.

Question 3

How is Blinatumomab administered?

Accepted Answer

Blinatumomab is administered Intravenous (IV). Administered as a continuous IV infusion via ambulatory infusion pump.

Question 4

What are the most common side effects of Blinatumomab?

Accepted Answer

The most commonly reported side effects of Blinatumomab (≥10% incidence) include: Pyrexia (>60%), Headache (~36%), Peripheral edema (~25%), Fatigue (~17%), Nausea (~25%) and others (14 total). Consult your oncologist for complete prescribing information.

Question 5

Does Blinatumomab have a black box warning?

Accepted Answer

Yes. Blinatumomab carries FDA black box warning(s) regarding: 1. Cytokine release syndrome (CRS): life-threatening or fatal; withhold or discontinue based on severity 2. Neurological toxicity including encephalopathy, seizures, speech disorders, and disturbances in consciousness; withhold or discontinue based on severity 3. Leukoencephalopathy including fatal progressive multifocal leukoencephalopathy (PML)

Question 6

Is Blinatumomab safe during pregnancy?

Accepted Answer

Blinatumomab pregnancy safety: Pregnancy Category not formally assigned (approved post-PLLR). Animal studies show fetal harm. Women of reproductive potential should use effective contraception during and for 48 hours after last dose. Avoid breastfeeding during treatment and for 48 hours after last dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

blinatumomab — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms